PPAR? gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uygur Chinese population residing in Northwestern China - 22/11/20
, Guoli Du e, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 11 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Objective |
To investigate the association of polymorphisms of Pro12Ala of peroxisome proliferator-activated receptor gamma (PPARγ) gene with clinical and biochemical parameters in Uygur Chinese population with non-alcoholic fatty liver (NAFLD)
Methods |
In this case–control study, we recruited 467 NAFLD cases and 524 controls. Examination of abdominal ultrasound, clinical and biochemical profiles, as well as polymerase chain reaction–restriction fragment length polymorphisms of Pro12Ala of PPARγ gene were performed. The association of PPARγ gene Pro12Ala variants with clinical and biochemical parameters was analyzed.
Results |
There was no statistically significant difference between NAFLD and control groups in the frequencies of genotypic and allele distribution (P>0.05), while significantly difference of genotypic (P=0.032) and allele (P=0.015) distribution was found between NAFLD and control groups in the obese. Using logistics multivariate regression analysis by adjusting age, sex, body mass index, diabetes, hyperuricemia and dyslipidemia, both Pro12Ala and Ala12Ala polymorphisms were not associated with the presence of NAFLD. However, above two polymorphisms were found to be related to NAFLD in obesity group (odds ratio=0.442, P=0.031 and odds ratio=0.039, P=0.010, respectively)
Conclusion |
In Uygur Chinese population, PPARr gene Ala variants reduce the risk of NAFLD in obese individuals.
Le texte complet de cet article est disponible en PDF.Keywords : Non-alcoholic fatty liver, Peroxisome proliferator-activated receptor-γ.
Plan
Vol 44 - N° 6
P. 894-904 - novembre 2020 Retour au numéro
Article précédent
- Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends
- Mohamed M. Gad, Anas M. Saad, Mohammed Faisaluddin, Mihnea Alexandru Gaman, Inas A. Ruhban, Khalid A. Jazieh, Muneer J. Al-Husseini, Carlos Roberto Simons-Linares, M. Bassam Sonbol, Bassam N. Estfan
- Adjuvanted recombinant HBV vaccine (HBV-AS04) is effective over extended follow-up in dialysis population. An open-label non randomized trial
- Fabrizio Fabrizi, Roberta Cerutti, Rebeca Garcia-Agudo, Cecilia Bellincioni, Giulia Porata, Giulia Frontini, Sami Aoufi-Rabih, Piergiorgio Messa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?